The development of vaccines to combat vaccine resistant cancers and infectious diseases has relied significantly on constructs employing subunit antigens. While the use of defined molecular antigens offers advantages in terms of safety and precision in immune response targeting, they are typically less immunogenic. Often, these vaccine formulations require an adjuvant, a substance that potentiates immune response. The critical roles of vaccine adjuvants lie in their ability to (1) enable the use of otherwise impotent antigens, (2) extend the benefits of vaccines to poor responders (e.g., older or immune-compromised patients), and (3) effect """"""""dose-sparing"""""""" of rare and expensive antigens in short supply (e.g., in an epidemic). The natural product saponin QS-21 is the adjuvant of choice in numerous promising antitumor and antiviral vaccine clinical trials, despite liabilities associated with toxicity, chemical instability, and lack of availability in pure form. This grant application comprises a unique multi-disciplinary approach toward the preparation, discovery, evaluation, and understanding of potent adjuvant molecules essential in the development of vaccines for cancer and infectious diseases.
The Specific Aims of this research program will involve: (1) the development of novel and efficient strategies for the chemical synthesis of designed non-natural structural variants of the saponin QS-21 possessing improved activity and stability with attenuated toxicity;(2) the evaluation of these novel compounds in mice to assess their ability to potentiate immune response, as well as their specific toxicity profiles;and (3) to employ small animal radio-imaging technologies, immunohistology, cytokine profiling, and affinity chromatography to gain insight into the adjuvant's as yet unknown mechanism of action. These efforts will address fundamental chemical and immunological questions associated with this extremely complex class of adjuvants, and holds the promise of yielding novel therapeutics in the vaccine arena.

Public Health Relevance

The success of antitumor and antiviral vaccines often requires the use of an adjuvant, a substance that is itself not necessarily immunogenic, but significantly enhances the immune response of a patient to a co- administered antigen. This grant application comprises a unique multi-disciplinary approach toward the preparation, discovery, evaluation, and understanding of potent adjuvant molecules essential in the development of vaccines for cancer and infectious diseases. These efforts will address fundamental chemical and immunological questions central to immune response potentiation, and holds the promise of yielding novel therapeutics in the vaccine arena.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI085622-01A1
Application #
7919772
Study Section
Special Emphasis Panel (ZRG1-BCMB-B (02))
Program Officer
Leitner, Wolfgang W
Project Start
2010-06-01
Project End
2014-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
1
Fiscal Year
2010
Total Cost
$862,703
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Fernández-Tejada, Alberto; Tan, Derek S; Gin, David Y (2016) Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis. Acc Chem Res 49:1741-56
Walkowicz, William E; Fernández-Tejada, Alberto; George, Constantine et al. (2016) Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities. Chem Sci 7:2371-2380
Fernández-Tejada, Alberto; Tan, Derek S; Gin, David Y (2015) Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants. Chem Commun (Camb) 51:13949-52
Fernández-Tejada, Alberto; Chea, Eric K; George, Constantine et al. (2014) Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol. Bioorg Med Chem 22:5917-23
Fernández-Tejada, Alberto; Chea, Eric K; George, Constantine et al. (2014) Development of a minimal saponin vaccine adjuvant based on QS-21. Nat Chem 6:635-43
Chea, Eric K; Fernandez-Tejada, Alberto; Damani, Payal et al. (2012) Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes. J Am Chem Soc 134:13448-57
Ragupathi, Govind; Gardner, Jeffrey R; Livingston, Philip O et al. (2011) Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 10:463-70
Gin, David Y; Slovin, Susan F (2011) Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant. Curr Drug ther 6:207-212